Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept

A potent VEGF inhibitor with novel antibody architecture and antigen binding mode has been developed. The molecule, hereafter referred to as VEGF dual dAb (domain antibody), was evaluated in vitro for binding to VEGF and for potency in VEGF-driven models and compared with other anti-VEGF biologics t...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Adam, Chung, Chun-Wa, Neu, Margarete, Burman, Manish, Batuwangala, Thil, Jones, Gavin, Tang, Chi-Man, Steward, Michael, Mullin, Michael, Tournier, Nadia, Lewis, Alan, Korczynska, Justyna, Chung, Vicky, Catchpole, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2016
Materias:
Molecular Biophysics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786692/
https://www.ncbi.nlm.nih.gov/pubmed/26728464
http://dx.doi.org/10.1074/jbc.M115.691162

Ejemplares similares

Ejemplares similares